ATE515260T1 - Stabile nanokapselsysteme für die verabreichung von wirkstoffen - Google Patents

Stabile nanokapselsysteme für die verabreichung von wirkstoffen

Info

Publication number
ATE515260T1
ATE515260T1 AT06380048T AT06380048T ATE515260T1 AT E515260 T1 ATE515260 T1 AT E515260T1 AT 06380048 T AT06380048 T AT 06380048T AT 06380048 T AT06380048 T AT 06380048T AT E515260 T1 ATE515260 T1 AT E515260T1
Authority
AT
Austria
Prior art keywords
administration
active ingredients
stable
nanocapsule systems
stable nanocapsule
Prior art date
Application number
AT06380048T
Other languages
English (en)
Inventor
Pena Ana Isabel Pabellon De Servi Vila
Luque Silvia Pabellon De Servi Suarez
Fernandez M Jose Pabellon De Alonso
Original Assignee
Advanced In Vitro Cell Technologies S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced In Vitro Cell Technologies S L filed Critical Advanced In Vitro Cell Technologies S L
Application granted granted Critical
Publication of ATE515260T1 publication Critical patent/ATE515260T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B01J13/02—Making microcapsules or microballoons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/11—Encapsulated compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/361—Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/55—Phosphorus compounds
    • A61K8/553—Phospholipids, e.g. lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/736—Chitin; Chitosan; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
    • A61K8/86—Polyethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/41—Particular ingredients further characterized by their size
    • A61K2800/413—Nanosized, i.e. having sizes below 100 nm
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT06380048T 2006-03-13 2006-03-13 Stabile nanokapselsysteme für die verabreichung von wirkstoffen ATE515260T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06380048A EP1834635B1 (de) 2006-03-13 2006-03-13 Stabile Nanokapselsysteme für die Verabreichung von Wirkstoffen

Publications (1)

Publication Number Publication Date
ATE515260T1 true ATE515260T1 (de) 2011-07-15

Family

ID=36743270

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06380048T ATE515260T1 (de) 2006-03-13 2006-03-13 Stabile nanokapselsysteme für die verabreichung von wirkstoffen

Country Status (17)

Country Link
US (1) US20090074824A1 (de)
EP (1) EP1834635B1 (de)
JP (1) JP5222739B2 (de)
KR (1) KR20080102303A (de)
CN (1) CN101426479B (de)
AR (1) AR059829A1 (de)
AT (1) ATE515260T1 (de)
AU (1) AU2007224471B2 (de)
BR (1) BRPI0709594A2 (de)
CA (1) CA2646338A1 (de)
DK (1) DK1834635T3 (de)
ES (1) ES2369244T3 (de)
IL (1) IL194005A0 (de)
PE (1) PE20080141A1 (de)
PL (1) PL1834635T3 (de)
PT (1) PT1834635E (de)
WO (1) WO2007104732A2 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2612872A3 (de) 2006-06-02 2014-01-22 Synedgen, Inc. Chitosan-Derivatverbindungen
US20080248508A1 (en) * 2006-08-17 2008-10-09 Shenda Baker Methods of making a chitosan product having an ultra-low endotoxin concentration and the ultra-low endotoxin chitosan product derived therefrom and method of accurately determining inflammatory and anti-inflammatory cellular response to such materials
MX2009013550A (es) * 2007-06-12 2010-12-02 Allen Christine Mezcla inyectable de polimero-lipido para suministro localizado de farmaco.
HRP20191104T1 (hr) 2007-09-25 2019-09-20 Solubest Ltd. Pripravci koji sadrže lipofilne aktivne spojeve i postupak za njihovu pripremu
EP2042166A1 (de) * 2007-09-25 2009-04-01 The Jordanian Pharmaceutical Manufacturing Co. Nanokapseln zur oralen Verabreichung von Proteinen
KR101199580B1 (ko) * 2008-08-06 2013-11-27 (주)에델프라우 국소 투여용 나노에멀젼
BRPI0805854A2 (pt) 2008-10-10 2010-08-24 Biolab Sanus Farmaceutica Ltda sistema nanoparticulado, processo de preparaÇço do mesmo, uso do mesmo, composiÇço fotoproterora, processo de preparaÇço da mesma, mÉtodo de prevenÇço de doenÇas e distérbios da pele
TWI328565B (en) * 2008-12-19 2010-08-11 Taiwan Textile Res Inst Dispersions of conductive carbon materials and methods for preparing the same
EP2762150A1 (de) 2009-03-12 2014-08-06 Nordic Bioscience A/S Behandlung von Diabetes und Stoffwechselsyndrom
ES2347119B2 (es) * 2009-04-22 2011-04-28 Universidad De Santiago De Compostela Nanocapsulas de poliarginina.
EP2266546A1 (de) * 2009-06-08 2010-12-29 Advancell Advanced in Vitro Cell Technologies,S.A. Verfahren zur Herstellung kolloidaler Systeme zur Abgabe von Wirkstoffen
EP2364600A1 (de) * 2010-02-18 2011-09-14 Nestec S.A. Flüssigkeitsgefüllte chitosan-anionische fettlösliche Kapseldispersionen
BRPI1002601E2 (pt) * 2010-06-01 2020-06-30 Embrapa Pesquisa Agropecuaria composição nanoestruturada de uso veterinário para administração de fármacos
US20110318406A1 (en) * 2010-06-23 2011-12-29 Eley Crispin G S Lecithin carrier vesicles and methods of making the same
CN103327970A (zh) * 2010-11-26 2013-09-25 约翰内斯堡威特沃特斯兰德大学 聚合物-脂质纳米粒子的聚合基质作为药物剂型
US9801829B2 (en) * 2011-04-29 2017-10-31 University Of Florida Research Foundation, Inc. Methods and systems of making nanostructures
DE102011076149A1 (de) * 2011-05-19 2012-11-22 Rovi Cosmetics International Gmbh Ladungsgeber für ein vesikuläres Trägersystem eines UV-Schutzmittels für die Haut oder die Haare
ES2366255B2 (es) * 2011-06-27 2012-08-08 Universidade De Santiago De Compostela Nanocomposiciones sacarídicas para la liberación de vacunas.
BR112014010701A2 (pt) 2011-11-02 2020-06-23 Keybioscience Ag Uso de um peptídeo
DK3095484T3 (en) 2011-11-02 2018-06-25 Keybioscience Ag CALCITONIN MIMETICS FOR THE TREATMENT OF DISEASES AND DISORDERS
AU2012339701B8 (en) * 2011-11-15 2017-11-16 Allergan, Inc. Autoclavable suspensions of cyclosporin A Form 2
US8968790B2 (en) 2011-12-09 2015-03-03 Shaker A. Mousa Nanoformulation of vitamin D derivatives and/or vitamin D metabolites
EP2625966A1 (de) 2012-02-13 2013-08-14 Bionanoplus, S.L. Nanopartikel mit einem pflanzlichen hydrophoben Protein und wassermischbare nichtflüchtige organische Lösung sowie Verwendungen davon
EP2934740B1 (de) * 2012-12-21 2019-12-11 Bracco Suisse SA Gasgefüllte mikrovesikel
CA3002989C (en) 2013-10-14 2021-03-16 Nanosphere Health Sciences, Llc Nanoparticle compositions and methods as carriers of nutraceutical factors across cell membranes and biological barriers
SI3321278T1 (sl) 2013-11-14 2019-04-30 Keybioscience Ag Mimetiki kalcitonina za zdravljenje bolezni in motenj
CN104117066B (zh) 2014-07-16 2016-03-02 陈凌 外敷用抗甲状腺软膏的制备方法
US11707436B2 (en) 2014-12-15 2023-07-25 Nanosphere Health Sciences Inc. Methods of treating inflammatory disorders and global inflammation with compositions comprising phospholipid nanoparticle encapsulations of NSAIDS
GB201500263D0 (en) 2015-01-08 2015-02-25 Keybioscience Ag Calcitonin analogues for treating diseases and disorders
CA2979184C (en) 2015-03-10 2020-09-08 Nanosphere Health Sciences, Llc Lipid nanoparticle compositions and methods as carriers of cannabinoids in standardized precision-metered dosage forms
PL229276B1 (pl) * 2015-07-17 2018-06-29 Univ Jagiellonski Nanokapsuła do przenoszenia związku lipofilowego i sposób jej wytwarzania
CN116999410A (zh) * 2015-08-11 2023-11-07 Eyesiu医疗股份有限公司 具有生物活性亲脂性化合物的聚乙二醇化脂质纳米粒
KR20180128025A (ko) * 2016-03-25 2018-11-30 아디쎄오 프랑스 에스에이에스 지용성 활성 성분을 포함하는 나노캡슐, 그 제조 방법 및 그 용도
GB201704429D0 (en) 2017-03-21 2017-05-03 Keybioscience Ag Calcitonin mimetics for treating diseases and disorders
GB201707955D0 (en) 2017-05-18 2017-07-05 Keybioscience Ag Dual amylin and calcitonin receptor agonists for treating diseases and disorders
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone
GB201813677D0 (en) 2018-08-22 2018-10-03 Keybioscience Ag Calcitonin mimetics for treating diseases and disorders
GB201813678D0 (en) 2018-08-22 2018-10-03 Keybioscience Ag Acylated calcitonin mimetics
CN109316602A (zh) * 2018-11-13 2019-02-12 西安力邦医药科技有限责任公司 一种长效镇痛并促进伤口愈合的复方缓释递药系统的组方与应用
SG11202106144VA (en) 2018-12-11 2021-07-29 Disruption Labs Inc Compositions for the delivery of therapeutic agents and methods of use and making thereof
KR102384808B1 (ko) * 2018-12-20 2022-04-08 주식회사 스킨메드 키토산으로 코팅된 나노 캡슐 및 이의 용도

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL101241A (en) * 1992-03-16 1997-11-20 Yissum Res Dev Co Pharmaceutical or cosmetic composition comprising stabilized oil-in-water type emulsion as carrier
US5527537A (en) * 1992-05-18 1996-06-18 Dietl; Hans Pharmaceutical preparation containing cyclosporine(s) for intravenous administration and a process for its production
US20030224022A1 (en) * 1993-01-19 2003-12-04 Amos Nussinovitch Hydrocolloid cellular solid matrices
US5744155A (en) * 1993-08-13 1998-04-28 Friedman; Doron Bioadhesive emulsion preparations for enhanced drug delivery
ES2093562B1 (es) * 1995-05-26 1997-07-01 Univ Santiago Compostela Estabilizacion de sistemas coloidales mediante formacion de complejos ionicos lipido-polisacarido.
US6649192B2 (en) * 1996-07-29 2003-11-18 Universidade De Santiago De Compostela Application of nanoparticles based on hydrophilic polymers as pharmaceutical forms
JP3441665B2 (ja) * 1999-02-04 2003-09-02 株式会社資生堂 （２−置換オキシフェニル）アルカンアミド誘導体及び養毛剤、皮膚外用剤
EP1190702A1 (de) * 2000-09-22 2002-03-27 Ciba SC Holding AG Emulgierte Chitosan Zusammensetzung
DE50105026D1 (de) * 2001-03-22 2005-02-10 Cognis Iberia Sl Nanokapseln
AU2002214233A1 (en) * 2001-11-01 2003-07-09 Novagali Pharma Sa Method and composition for dry eye treatment

Also Published As

Publication number Publication date
DK1834635T3 (da) 2011-10-24
WO2007104732A3 (en) 2007-11-08
JP5222739B2 (ja) 2013-06-26
CN101426479B (zh) 2012-10-10
CA2646338A1 (en) 2007-09-20
EP1834635B1 (de) 2011-07-06
EP1834635A1 (de) 2007-09-19
AU2007224471B2 (en) 2013-05-02
KR20080102303A (ko) 2008-11-24
AU2007224471A1 (en) 2007-09-20
CN101426479A (zh) 2009-05-06
AR059829A1 (es) 2008-04-30
ES2369244T3 (es) 2011-11-28
PL1834635T3 (pl) 2012-01-31
IL194005A0 (en) 2011-08-01
WO2007104732A2 (en) 2007-09-20
PE20080141A1 (es) 2008-03-04
BRPI0709594A2 (pt) 2011-07-19
US20090074824A1 (en) 2009-03-19
JP2009530241A (ja) 2009-08-27
PT1834635E (pt) 2011-10-13

Similar Documents

Publication Publication Date Title
ATE515260T1 (de) Stabile nanokapselsysteme für die verabreichung von wirkstoffen
ATE509636T1 (de) Kombination aus einem cholinesterase-hemmer und einer verbindung mit 5-ht6-rezeptor-affinität
EP2081550A4 (de) Beschichtung von kapseln mit pharmazeutischen wirkstoffen
BRPI0716196A2 (pt) Sistemas de distribuição de fármacos que compreendem soluções sólidas de fármacos fracamente básicos.
IL243709A0 (en) Devices, systems and methods for medicament delivery
BRPI0718688A2 (pt) Composições de baixa irritação e métodos para preparar as mesmas.
DK3984528T3 (da) Farmaceutiske sammensætninger, som omfatter nilotinib
ATE482618T1 (de) Wirkstoffkombinationen
DK2054042T3 (da) Fremgangsmåder til fremstilling af biologisk aktive forbindelser i nanopartikelform
PT3111926T (pt) Composições, métodos e sistemas para entrega respiratória de dois ou mais agentes ativos
NL2000690A1 (nl) Gestabiliseerde farmaceutische samenstellingen omvattende fesoterodine.
DK2073795T3 (da) Misbrugssikret lægemiddelformulation
EP2076244A4 (de) Wässrige systeme für die zubereitung pharmazeutischer verbindungen auf fettbasis, zusammensetzungen, verfahren und ihre verwendung
EP2951777A4 (de) Aktiver-angreifer-protokoll für notrufannahme
ATE484194T1 (de) Wirkstoffkombinationen
IL193274A0 (en) Pharmaceutical formulation for aerosols, comprising two or more active agents and at least one surfactant
DK3103448T3 (da) Farmaceutiske sammensætninger, der omfatter en S1P-modulator
MX2009006567A (es) Pirimidinilpirazoles como principios activos insecticidas y parasiticidas.
EP2078731A4 (de) Anti-hb-egf-antikörper als wirkstoff enthaltende pharmazeutische zusammensetzung
BRPI0917625A2 (pt) substratos que fornecem liberações multiplas de agentes ativos
ZA200809864B (en) Pharmaceutical formulations for the sustained release of active ingredients(s), as well as their applications, especially therapeutic
PL2081547T3 (pl) Postać galenowa do podawania składników czynnych poprzez śluzówkę
BRPI0809661A2 (pt) Composição farmacêutica estabilizada contendo pregabalina
CL2007001838A1 (es) Compuestos derivados de 4-oxoquinolina; composicion farmaceutica; y uso del compuesto para la produccion de un agente anti-vih.
DK1839498T3 (da) Valleprotein-fremføringsmiddel til afgivelse af aktivt middel